ImmunoPrecise Antibodies (IPA) 6-K 16 Sep 24 2024 Q1 Current report (foreign) Financial data

Cover Page

Cover Page	3 Months Ended
	Jul. 31, 2024
Cover [Abstract]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jul. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Registrant Name	ImmunoPrecise Antibodies Ltd.
Entity Central Index Key	0001715925
Current Fiscal Year End Date	--04-30
Entity Address, Address Line One	3204 - 4464 Markham Street
Entity Address, City or Town	Victoria
Entity Address, State or Province	BC
Entity Address, Postal Zip Code	V8Z 7X8

Condensed Interim Consolidated

Condensed Interim Consolidated Statements of Financial Position - CAD ($) $ in Thousands	Jul. 31, 2024	Apr. 30, 2024
Current assets
Cash	$ 3,913	$ 3,459
Amounts receivable, net	2,509	3,790
Taxes receivable	324	414
Inventory	1,869	2,139
Unbilled revenue	684	277
Prepaid expenses	1,720	1,408
Total current assets	11,019	11,487
Restricted cash	87	86
Deposit on equipment	485	475
Property and equipment	16,437	16,696
Intangible assets	23,424	23,557
Goodwill	7,847	7,687
Total assets	59,299	59,988
Current liabilities
Accounts payable and accrued liabilities	4,816	4,372
Deferred revenue	1,301	1,353
Income taxes payable	560	553
Leases	1,605	1,563
Deferred acquisition payments	292	284
Debentures, net	2,599	0
Current liabilities	11,173	8,125
Leases	11,896	12,118
Deferred income tax liability	3,376	4,067
Total liabilities	26,445	24,310
SHAREHOLDERS' EQUITY
Share capital	120,264	119,773
Contributed surplus	12,552	12,387
Accumulated other comprehensive loss	2,597	2,078
Accumulated deficit	(102,559)	(98,560)
Equity	32,854	35,678
Total liabilities and shareholders' equity	$ 59,299	$ 59,988

Condensed Interim Consolidate_2

Condensed Interim Consolidated Statements of Comprehensive Loss $ in Thousands, € in Millions	3 Months Ended
	Jul. 31, 2024 CAD ($) $ / shares shares	Jul. 31, 2024 EUR (€) shares	Jul. 31, 2023 CAD ($) $ / shares shares
Profit or loss [abstract]
REVENUE	$ 5,263		$ 5,688
COST OF SALES	2,907		2,893
GROSS PROFIT	2,356		2,795
EXPENSES
Research and development	1,642		947
Sales and marketing	718		1,063
General and administrative	4,163		3,987
Amortization of intangible assets	606		847
Total expenses	7,129		6,844
Loss before other income (expenses) and income taxes	(4,773)		(4,049)
OTHER INCOME (EXPENSES)
Grant income	146	€ 0.1	283
Interest, accretion and other income	(2)		8
Unrealized foreign exchange loss	(146)		(73)
Other income (expenses)	(2)		218
Loss before income taxes	(4,775)		(3,831)
Income taxes	776		415
NET LOSS FOR THE PERIOD	(3,999)		(3,416)
Items that will be reclassified subsequently to loss
Exchange difference on translating foreign operations	519		(1,170)
COMPREHENSIVE LOSS FOR THE PERIOD	$ (3,480)		$ (4,586)
LOSS PER SHARE - BASIC | $ / shares	$ (0.15)		$ (0.14)
LOSS PER SHARE - DILUTED | $ / shares	$ (0.15)		$ (0.14)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING | shares	27,132,355	27,132,355	25,050,260

Condensed Interim Consolidate_3

Condensed Interim Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in Thousands	Total	Share Capital	Contributed Surplus	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Beginning balance at Apr. 30, 2023	$ 58,515	$ 117,470	$ 10,796	$ 2,690	$ (72,441)
Beginning balance, shares at Apr. 30, 2023	25,050,260
Share-based expense	$ 823		823
Comprehensive loss for the period	(4,586)			(1,170)	(3,416)
Ending balance at Jul. 31, 2023	$ 54,752	117,470	11,619	1,520	(75,857)
Ending balance, shares at Jul. 31, 2023	25,050,260
Beginning balance at Apr. 30, 2024	$ 35,678	119,773	12,387	2,078	(98,560)
Beginning balance, shares at Apr. 30, 2024	26,944,500
Shares issued pursuant to ATM	$ 491	491
Shares issued pursuant to ATM, shares	357,760
Share-based expense	$ 165		165
Comprehensive loss for the period	(3,480)			519	(3,999)
Ending balance at Jul. 31, 2024	$ 32,854	$ 120,264	$ 12,552	$ 2,597	$ (102,559)
Ending balance, shares at Jul. 31, 2024	27,302,260

Condensed Interim Consolidate_4

Condensed Interim Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Operating activities:
Net loss for the period	$ (3,999)	$ (3,416)
Items not affecting cash:
Amortization and depreciation	1,395	1,494
Deferred income taxes	(645)	(216)
Accretion	3	5
Foreign exchange	155	113
Share-based payments	165	823
Items not affecting cash	(2,926)	(1,197)
Amounts receivable	1,274	(62)
Inventory	299	(55)
Unbilled revenue	(400)	(446)
Prepaid expenses	(293)	175
Accounts payable and accrued liabilities	530	242
Sales and income taxes payable and receivable	(249)	635
Deferred revenue	(59)	155
Net cash used in operating activities	(1,824)	(553)
Investing activities:
Purchase of property and equipment	(263)	(136)
Deferred acquisition payment	0	(146)
Sale of QVQ Holdings BV shares	0	85
Net cash used in investing activities	(263)	(197)
Financing activities:
Proceeds on share issuance, net of transaction costs	491	0
Repayment of leases	(394)	(405)
Debenture	2,599	0
Net cash used in financing activities	2,696	(405)
Increase (decrease) in cash during the period	609	(1,155)
Foreign exchange	(154)	(398)
Cash – beginning of the year	3,545	8,366
Cash – end of the year	4,000	6,813
Cash is comprised of:
Cash	3,913	6,729
Restricted cash	87	84
Cash paid for interest	0	0
Cash paid for income tax	$ 0	$ 0

Nature of Operations

Nature of Operations	3 Months Ended
	Jul. 31, 2024
Disclosure Of Nature Of Operations [Abstract]
Nature Of Operations	1. NATURE OF OPERATIONS ImmunoPrecise Antibodies Ltd. (the "Company" or “IPA”) was incorporated under the laws of Alberta on November 22, 1983. The Company is listed on the NASDAQ Global Market (“Nasdaq”) under the trading ticker symbol “IPA.” The Company is a supplier of custom antibody discovery services. The address of the Company's corporate office is 3204 – 4464 Markham Street, Victoria, BC, Canada V8Z 7X8. Going concern basis The condensed interim consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern. The Company has incurred operating losses since its inception, including $ 4.0 million for the three months ended July 31, 2024, and has accumulated a deficit of $ 102.6 million as of July 31, 2024. The Company had $4.0 million cash on hand as of July 31, 2024. The Company expects its cash on hand as of July 31, 2024 will be insufficient to fund the Company's operations for at least one year from the date these financial statements are available to be issued. These conditions raise material uncertainties which cast significant doubt as to whether the Company will be able to continue as a going concern should it not be able to obtain financing necessary to fund its planned revenue growth and working capital requirements. The Company will need to raise additional funds to finance its operations and strategic goals and there can be no assurances that sufficient funding, including adequate financing, will be available. The ability of the Company to arrange additional financing in the future depends in part on the prevailing capital market conditions and profitability of its operations. If the Company is unable to raise sufficient funds, reductions in expenditures will be required, and this may impact the future growth plans of the Company.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Jul. 31, 2024
Basis Of Accounting [Abstract]
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION (a) Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"), and include the significant accounting policies as described in Note 3. Certain items have been reclassified in the prior year financial statements to conform to the presentation and classification used in the current year. These reclassifications had no effect on the Company's consolidated operating results, financial position or cash flows. These condensed interim consolidated financial statements were approved by the Company's Board of Directors. (b) Basis of measurement These condensed interim consolidated financial statements have been prepared on the historical cost basis. In addition, these condensed interim consolidated financial statements have been prepared using the accrual basis of accounting, except for cashflow information. (c) Basis of consolidation These condensed interim consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company: Name of Subsidiary % Equity Country of Functional Currency ImmunoPrecise Antibodies (Canada) Ltd. 100 % Canada Canadian dollar ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA") 100 % USA U.S. dollar ImmunoPrecise Antibodies (N.D.) Ltd. 100 % USA U.S. dollar ImmunoPrecise Antibodies (MA) LLC 100 % USA U.S. dollar Talem Therapeutics LLC ("Talem") 100 % USA U.S. dollar ImmunoPrecise Netherlands B.V. 100 % Netherlands Euro ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe") 100 % Netherlands Euro BioStrand B.V. 100 % Belgium Euro Idea Family B.V. 100 % Belgium Euro BioKey B.V. 100 % Belgium Euro BioClue B.V. 100 % Belgium Euro ImmunoPrecise Antibodies (Quebec), Ltd. 100 % Canada Canadian dollar 9438-9244 Quebec, Inc. 100 % Canada Canadian dollar Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with an entity and has the ability to affect those returns through its power over the investee. Subsidiaries are fully consolidated from the date on which control is obtained and continue to be consolidated until the date that such control ceases. Intercompany balances, transactions and unrealized intercompany gains and losses are eliminated upon consolidation. (d) Functional and presentation currency The functional currency of a company is the currency of the primary economic environment in which the company operates. The presentation currency for a company is the currency in which the company chooses to present its financial statements. The presentation currency of the Company is the Canadian dollar. Foreign currency translation Entities whose functional currencies differ from the presentation currency are translated into Canadian dollars as follows: assets and liabilities – at the closing rate as at the reporting date, and income and expenses – at the average rate of the period. All resulting changes are recognized in other comprehensive income as cumulative translation differences. Foreign currency transactions Transactions in foreign currencies are translated into the functional currency at exchange rates at the date of the transactions. Foreign currency monetary assets and liabilities are translated at the functional currency exchange rate at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. All gains and losses on translation of these foreign currency transactions are included in profit or loss. When the Company disposes of its entire interest in a foreign operation, or loses control, joint control, or significant influence over a foreign operation, the foreign currency gains or losses accumulated in other comprehensive income related to the foreign operation are recognized in profit or loss. If an entity disposes of part of an interest in a foreign operation which remains a subsidiary, a proportionate amount of foreign currency gains or losses accumulated in other comprehensive income related to the subsidiary are reallocated between controlling and non-controlling interests. (e) Correction of immaterial error During the first quarter of fiscal year 2025, we corrected an immaterial error related to fiscal years 2023 and 2024. The adjustment related to the correction of the recognition of a deferred tax asset and resulting offset with the deferred income tax liability for fiscal years 2023 and 2024. The error had the impact of overstating the deferred tax liability and overstating the net loss in fiscal 2023 and 2024. Management evaluated the effect of the adjustment on previously issued interim and annual consolidated financial statements in accordance with IFRS guidelines and concluded that it was immaterial to the interim and annual periods. As a result, in accordance with IFRS, we corrected our Consolidated Statements of Financial Position and Comprehensive Loss as of July 31, 2024. The effects of this adjustment on our Consolidated Statements of Financial Position and Comprehensive Loss as of July 31, 2024 are as follows: Previously reported Adjustments As adjusted Balance sheet items: (in thousands) 4/30/2024 4/30/2024 4/30/2024 Deferred income tax liability 5,825 ( 1,758 ) 4,067 Total liabilities 26,067 ( 1,757 ) 24,310 Accumulated deficit ( 100,265 ) 1,705 ( 98,560 ) Accumulated other comprehensive loss 2,025 53 2,078 Total shareholders' equity 33,921 1,757 35,678 Previously reported Adjustments As adjusted Income statement items: (in thousands) 7/31/2023 7/31/2023 7/31/2023 Income taxes 262 153 415 Net loss for the period ( 3,565 ) 149 ( 3,416 ) Exchange difference on translating foreign operations ( 1,216 ) 46 ( 1,170 ) Comprehensive loss for the period ( 4,781 ) 195 ( 4,586 ) Basic and diluted loss per share* (0.14 ) 0.00 (0.14 ) * Because of the net loss, basic and diluted loss per share are the same given potential dilutive common shares are excluded from the computation as their effect would be anti-dilutive.

Adoption of New Accounting Stan

Adoption of New Accounting Standards	3 Months Ended
	Jul. 31, 2024
Disclosure of initial application of standards or interpretations [abstract]
Adoption of New Accounting Standards	3. ADOPTION OF NEW ACCOUNTING STANDARDS Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) The amendments to IAS 1 provide a more general approach to the classification of liabilities based on the contractual arrangements in place at the reporting date. These amendments are effective for reporting periods beginning on or after January 1, 2024, which is our fiscal year ending April 30, 2025. We adopted these amendments in our first fiscal quarter ending July 31, 2024 with no impact noted to our classification of liabilities.

Critical Accounting Estimates A

Critical Accounting Estimates And Judgements	3 Months Ended
	Jul. 31, 2024
Critical Accounting Estimates And Judgments [Abstract]
CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS	4. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS The preparation of the condensed interim consolidated financial statements in conformity with IFRS required estimates and judgments that affect the amounts reported in the financial statements. Actual results could differ from these estimates and judgments. Estimates are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the year in which the estimate is revised. Estimates and judgments applied in the preparation of the condensed interim consolidated financial statements are the same as those presented in the Company’s audited annual financial statements for the year ended April 30, 2024.

Property and Equipment

Property and Equipment	3 Months Ended
	Jul. 31, 2024
Disclosure of detailed information about property, plant and equipment [abstract]
PROPERTY AND EQUIPMENT	5. PROPERTY AND EQUIPMENT The table below includes both property and equipment and right-of-use assets. (in thousands) Computer Furniture & Computer Building Automobile Leasehold Lab WIP - Total Cost: Balance, April 30, 2023 288 53 50 9,085 167 626 6,473 31 16,773 Additions 56 — — 7,826 1 27 1,316 — 9,226 Disposals ( 111 ) ( 31 ) ( 49 ) ( 1,634 ) — ( 344 ) ( 2,554 ) — ( 4,723 ) Foreign exchange ( 4 ) ( 1 ) ( 1 ) ( 133 ) ( 3 ) ( 2 ) ( 92 ) — ( 236 ) Balance, April 30, 2024 229 21 — 15,144 165 307 5,143 31 21,040 Additions — — — — — — 46 215 261 Foreign exchange 4 — — 242 3 2 78 — 329 Balance, July 31, 2024 233 21 — 15,386 168 309 5,267 246 21,630 Accumulated Depreciation: Balance, April 30, 2023 157 33 50 1,752 57 388 3,913 — 6,350 Depreciation 101 4 — 1,723 56 58 849 — 2,791 Disposals ( 110 ) ( 31 ) ( 49 ) ( 1,606 ) — ( 344 ) ( 2,554 ) — ( 4,694 ) Foreign exchange ( 2 ) — ( 1 ) ( 38 ) ( 1 ) — ( 61 ) — ( 103 ) Balance, April 30, 2024 146 6 — 1,831 112 102 2,147 — 4,344 Depreciation 25 1 — 473 14 15 255 — 783 Foreign exchange 3 ( 1 ) — 31 2 1 30 — 66 Balance, July 31, 2024 174 6 — 2,335 128 118 2,432 — 5,193 Net Book Value: April 30, 2024 83 15 — 13,313 53 205 2,996 31 16,696 July 31, 2024 59 15 — 13,051 40 191 2,835 246 16,437

Intangible Assets

Intangible Assets	3 Months Ended
	Jul. 31, 2024
Disclosure of detailed information about intangible assets [abstract]
INTANGIBLE ASSETS	6. INTANGIBLE ASSETS Changes in the value of the intangible assets during the three months ended July 31, 2024 and the year ended April 30, 2024 are as follows: (in thousands) Internally Intellectual Proprietary Certifications Customer List Total Cost: Balance, April 30, 2023 33 35,143 8,103 139 198 43,616 Impairments and disposals — ( 3,830 ) ( 40 ) — ( 193 ) ( 4,063 ) Foreign exchange — ( 595 ) ( 137 ) ( 3 ) ( 5 ) ( 740 ) Balance, April 30, 2024 33 30,718 7,926 136 — 38,813 Foreign exchange — 641 166 3 — 810 Balance, July 31, 2024 33 31,359 8,092 139 — 39,623 Accumulated Amortization: Balance, April 30, 2023 14 4,775 7,633 136 132 12,690 Amortization 19 2,666 216 2 65 2,968 Disposals — — — — ( 193 ) ( 193 ) Foreign exchange — ( 74 ) ( 128 ) ( 2 ) ( 4 ) ( 208 ) Balance, April 30, 2024 33 7,367 7,721 136 — 15,257 Amortization — 589 17 — — 606 Foreign exchange — 170 163 3 — 336 Balance, July 31, 2024 33 8,126 7,901 139 — 16,199 Net Book Value: April 30, 2024 — 23,351 205 — — 23,556 July 31, 2024 — 23,233 191 — — 23,424

Convertible Debentures

Convertible Debentures	3 Months Ended
	Jul. 31, 2024
Convertible Debentures [Abstract]
CONVERTIBLE DEBENTURES	7. CONVERTIBLE DEBENTURES On July 16, 2024 YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”), entered into a securities purchase agreement (the "Securities Purchase Agreement") under which the Company agreed to sell and issue to Yorkville U.S.$ 3.0 million aggregate principal amount of convertible debentures (the “Convertible Debentures”) in two tranches and at a purchase price of 95 % of the aggregate principal amount. The Convertible Debentures are convertible into common shares of the Company (the “Common Shares”). The sale and issue of the first tranche consists of U.S.$ 2.0 million principal amount of Convertible Debentures and was completed on July 16, 2024 (the “First Closing”) with a maturity date of July 16, 2025. The sale and issue of the second tranche consists of U.S.$ 1.0 million principal amount of Convertible Debentures and was completed on August 16, 2024. Each Convertible Debenture is an unsecured obligation of the Company and is guaranteed by certain of the Company’s subsidiaries. The Convertible Debentures incur interest at a rate of 8.0 % per annum. The outstanding principal amount, and accrued and unpaid interest, if any, on the Convertible Debentures must be paid by the Company in cash when the same becomes due and payable under the terms of the Convertible Debentures at their stated maturity, upon their redemption or otherwise. Subject to certain limitations contained in the securities Purchase Agreement and the Convertible Debentures, the Convertible Debentures are redeemable by the Company and convertible by the holders if certain conditions are met. In connection with the offering, the Company and Yorkville entered into a customary Registration Rights Agreement (the “Registration Rights Agreement”) pursuant to which the Company has agreed to provide certain registration rights to Yorkville under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”).

Leases

Leases	3 Months Ended
	Jul. 31, 2024
Presentation of leases for lessee [abstract]
LEASES	8. LEASES The Company has leases for lab and office space and automobiles. Each lease is reflected in the consolidated statement of financial position as a right-of-use asset and a lease liability. The Company classifies right-of-use assets in a consistent manner to its property and equipment. The following is a schedule of the Company’s future minimum lease payments related to the equipment and automobiles under finance lease and the office lease obligation: Total cash outflow for leases during the three months ended July 31, 2024 wa s $ 0.4 million (2023 - $ 0.4 million). (in thousands) $ 2025 1,859 2026 2,452 2027 2,448 2028 2,442 2029 2,138 More than 5 years 5,836 Total minimum lease payments 17,175 Less: imputed interest ( 3,674 ) Total present value of minimum lease payments 13,501 Less: Current portion ( 1,605 ) Non-current portion 11,896 The nature of the Company’s leases by type of right-of-use asset as at July 31, 2024 is as follows: Right-of-use assets Right-of-use asset type No. of right-of-use assets leased Range of remaining term Average remaining lease term No. of leases with extension options No. of leases with options to purchase No. of leases with variable payments linked to an index No. of leases with termination options Lab and office facilities 3 5.4 - 9.4 years 7.5 years 1 — 2 2 Automobiles 5 0.3 - 2.4 years .9 years — — 5 5 The changes in the value of right-of-use assets during the three months ended July 31, 2024 and the year ended April 30, 2024 are as follows: (in thousands) Building Automobile Total Cost: Balance, April 30, 2023 9,085 167 9,252 Additions 7,826 1 7,827 Disposals ( 1,634 ) — ( 1,634 ) Foreign exchange ( 133 ) ( 3 ) ( 136 ) Balance, April 30, 2024 15,144 165 15,309 Foreign exchange 242 3 245 Balance, July 31, 2024 15,386 168 15,554 Accumulated Depreciation: Balance, April 30, 2023 1,752 57 1,809 Depreciation 1,723 56 1,779 Disposals ( 1,606 ) — ( 1,606 ) Foreign exchange ( 37 ) ( 1 ) ( 38 ) Balance, April 30, 2024 1,832 112 1,944 Depreciation 473 14 487 Foreign exchange 31 3 34 Balance, July 31, 2024 2,336 129 2,465 Net Book Value: April 30, 2024 13,312 53 13,365 July 31, 2024 13,050 39 13,089 Lease payments not recognized as a liability The Company has elected not to recognize a lease liability for leases with an expected term of 12 months or less. Additionally, certain variable lease payments are not permitted to be recognized as lease liabilities and are recognized in profit and loss as incurred. The expense relating to payments not included in the measurement of the lease liability during the three months ended July 31, 2024 and 2023 are as follows: (in thousands) 2024 2023 Leases of low value assets 3 4 Variable lease payments 125 36 128 40

Share Capital

Share Capital	3 Months Ended
	Jul. 31, 2024
Disclosure of classes of share capital [abstract]
SHARE CAPITAL	9. SHARE CAPITAL a) Authorized: Unlimited common shares without par value. b) Share capital transactions: 2024 Transactions During the year ended April 30, 2024, the Company issued 1,265,000 common shares in an underwritten public offering, including 165,000 common shares issued pursuant to the full exercise by the underwriter of its over-allotment option. The public offering price for each common share, before the underwriter's discount and commissions, was U.S.$ 1.00 . During the year ended April 30, 2024, the Company established an at-the-market equity offering facility with Clear Street LLC ("ATM Facility"), replacing its previous at-the-market equity offering facility with Jefferies LLC, which was terminated on February 1, 2024. An Open Market Sales Agreement ("ATM Agreement") was entered into with Clear Street LLC, as sole sales agent ("Agent") on February 23, 2024. The Company is entitled, at its discretion and from time-to-time during the term of the ATM Agreement, to sell, through the Agent common shares of the Company. On February 23, 2024, in connection with the ATM Facility, the Company filed a prospectus supplement permitting the sales of common shares having an aggregate gross sales price of up to U.S.$ 60.0 million. On July 29, 2024, the Company filed an amendment to the prospectus supplement to reduce the aggregate gross sales price of Common Shares under the Clear Street ATM Facility to U.S.$ 8.8 million. Sales of the common shares will be made in transactions that are deemed to be "at-the-market distributions" as defined in Rule 415(a)(4) of the U.S. Securities Act, including, without limitation, sales made directly on Nasdaq or any other existing trading market for the common shares in the United States. Common shares will only be sold on the facilities of an exchange or market outside Canada to purchasers who the Company has no reason to believe are resident in Canada and, in all others cases, to purchasers who are not located or resident in Canada. The Company will determine, at its sole discretion, the date, minimum price and maximum number of common shares to be sold under the ATM Facility. The common shares will be distributed from time to time in negotiated transactions, at market prices prevailing at the time of sale, at prices relating to such prevailing market prices, and/or in any other manner permitted by applicable law. As such, the prices may vary between purchasers over time. The Company is not required to sell any common shares at any time during the term of the ATM Facility. During the year ended April 30, 2024, 629,240 common shares were sold under the ATM with proceeds net of commissions of $ 1.8 million. 2025 Transactions During the three months ended July 31, 2024, the Company sold 357,760 common shares between the dates of May 1, 2024 through July 26, 2024, they were sold under the ATM Facility with proceeds net of commissions of $ 0.5 million. c) Options The following table summarizes stock option awards during the three months ended July 31, 2024 and the year ended April 30, 2024, including the grant date fair value determined using the Black-Scholes option pricing model: Black-Scholes Option Pricing Model Inputs Grant date Stock options granted Exercisable price/option Awarded to Share price on grant date Dividend yield Expected volatility Risk-free rate Expected life Fair value January 19, 2024 (1) 240,000 1.48 Directors 1.48 (2) 0 % 77 % 3.64 % 5.0 years $ 0.4 million January 4, 2023 (1) 8,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 12 thousand January 23, 2023 (1) 8,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 12 thousand March 1, 2023 (1) 8,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 12 thousand March 15, 2023 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand April 2, 2023 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand May 8, 2023 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand May 23, 2023 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand June 11, 2023 (1) 8,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 12 thousand August 8, 2023 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand November 13, 2023 (1) 8,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 12 thousand January 1, 2024 (1) 12,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 18 thousand February 1, 2024 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand February 19, 2024 (1) 12,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 18 thousand February 20, 2024 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand (1) Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date . (2) Priced in U.S.$ Expected volatility of options granted is based on the historical volatility of the company from January 1, 2019 to the option grant date. During the three months ended July 31, 2024 the Company has recorded $ 0.2 million (2023 - $ 0.8 million) of share-based payments expense. The changes in the stock options for the three months ended July 31, 2024 and the year ended April 30, 2024 are as follows: Number of Weighted Weighted Balance, April 30, 2023 (outstanding) 1,884,428 8.03 3.27 Granted 332,000 2.02 — Expired ( 577,335 ) 7.15 — Forfeited ( 117,726 ) 4.15 — Balance, April 30, 2024 (outstanding) 1,521,367 8.29 2.88 Expired ( 20,000 ) 14.50 — Forfeited ( 10,751 ) 1.45 — Balance, July 31, 2024 (outstanding) 1,490,616 7.14 3.19 Unvested ( 429,428 ) 3.39 4.84 Exercisable, July 31, 2024 1,061,188 8.66 2.53 Details of the options outstanding as at July 31, 2024 are as follows: Expiry Date Exercise Remaining Options Unvested Vested September 1, 2025 8.50 1.09 220,000 - 220,000 January 6, 2026 20.30 1.44 146,000 - 146,000 January 2, 2026 6.89 1.42 5,650 - 5,650 January 7, 2027 7.94 2.44 235,000 - 235,000 May 15, 2027 8.30 2.45 16,000 - 16,000 February 19, 2027 (1) 5.79 2.79 64,000 - 64,000 February 19, 2028 (1) 5.68 2.56 7,265 - 7,265 January 19, 2034 (2) 5.68 3.56 475,452 158,484 316,968 January 4, 2033 (3) 2.05 4.47 240,000 204,444 35,556 January 23, 2033 (3) 2.04 8.44 8,000 5,167 2,833 March 1, 2033 (3) 2.04 8.49 8,000 5,167 2,833 March 15, 2033 (3) 2.04 8.59 8,000 5,500 2,500 April 2, 2033 (3) 2.04 8.63 1,249 - 1,249 May 8, 2033 (3) 2.04 8.68 4,000 2,833 1,167 May 23, 2033 (3) 2.04 8.78 4,000 2,917 1,083 June 11, 2033 (3) 2.04 8.82 4,000 2,917 1,083 August 8, 2033 (3) 2.04 8.87 8,000 6,000 2,000 November 13, 2033 (3) 2.04 9.03 4,000 4,000 — January 1, 2034 (3) 2.04 9.29 8,000 8,000 — February 1, 2034 (3) 2.04 9.43 12,000 12,000 — February 19, 2034 (3) 2.04 9.51 4,000 4,000 — February 20, 2034 (3) 2.04 9.56 8,000 8,000 — 7.14 3.19 1,490,616 429,428 1,061,188 (1) Exercise price of U.S. $ 4.10 . The figure in the table above is translated at the July 31, 2024 rate. (2) Exercise price of U.S. $ 1.48 . The figure in the table above is translated at the July 31, 2024 rate. (3) Exercise price of U.S. $ 1.47 . The figure in the table above is translated at the July 31, 2024 rate. d) Finder’s Warrants There were no changes in the finder's warrants during the three months ended July 31, 2024. Details of the finder’s warrants outstanding as at July 31, 2024 are as follows: Number of Weighted average Weighted average life Balance, April 30, 2023 130,111 22.77 2.77 Issued 56,650 1.37 4.61 Balance, April 30, 2024 186,761 16.44 2.62 Exercised — — — Balance, July 31, 2024 186,761 16.63 2.38 Details of the finder's warrants outstanding as at April 30, 2024 are as follows: Expiry Date Exercise price Remaining life Warrants February 3, 2026 (1) 23.27 1.51 130,111 December 8, 2028 (2) 1.38 4.37 56,650 (1) Exercise price of U.S. $ 16.81 . The figure in the table above is translated at the July 31, 2024 rate. (2) Exercise price of U.S. $ 1.00 . The figure in the table above is translated at the July 31, 2024 rate.

Employee Remuneration

Employee Remuneration	3 Months Ended
	Jul. 31, 2024
Disclosure of employee benefits expenses [abstract]
EMPLOYEE REMUNERATION	10. EMPLOYEE REMUNERATION Expenses recognized for employee benefits for the three months ended July 31, 2024 and 2023 are detailed below: (in thousands) 2024 2023 Wages, salaries 2,674 2,780 Employee benefits 210 340 Payroll taxes 200 181 Severance — 60 Share-based payments 165 823 3,249 4,184

Related Party Transactions

Related Party Transactions	3 Months Ended
	Jul. 31, 2024
Related party transactions [abstract]
RELATED PARTY TRANSACTIONS	11. RELATED PARTY TRANSACTIONS Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company. Key management consists of Dr. Jennifer Bath, President and CEO; Kristin Taylor, CFO; Brad McConn, former Chief Financial Officer; Dr. Ilse Roodink, Chief Scientific Officer; Lisa Helbling, former Director, Dr. Barry Duplantis, former Vice President of Client Relations; and Directors of the Company. During the three months ended July 31, 2024 and 2023, the compensation for key management is as follows: (in thousands) 2024 2023 Salaries and other short-term benefits 613 647 Severance (included in salaries) — 60 Share-based payments 116 516 Director compensation (included in salaries) 84 71 813 1,294 At July 31, 2024, included in accounts payable and accrued liabilities is $ 0.3 million (April 30, 2023 - $ 1.2 million) due to related parties. The amounts payable are non-interest bearing and unsecured. These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties, unless otherwise noted.

Commitments

Commitments	3 Months Ended
	Jul. 31, 2024
Commitments [Abstract]
COMMITMENTS	12. COMMITMENTS The share purchase agreement related to the acquisition of BioStrand includes contingent earnout payments based on 20 % of the EBITDA of BioStrand, as defined in the share purchase agreement, over a 7-year period ending April 30, 2029, which shall not exceed in total € 12.0 million. The Company has determined these payments relate to post-acquisition services because they are contingent on the employment of two key employees and will be expensed in the period earned. As of July 31, 2024, the Company has not incurred any related earnout payments and the unpaid commitment related to the BioStrand earnout is € 12.0 million.

Grant and Subsidy Income

Grant and Subsidy Income	3 Months Ended
	Jul. 31, 2024
Grant And Subsidy Income [Abstract]
GRANT AND SUBSIDY INCOME	13. GRANT AND SUBSIDY INCOME During May 2022, the Company received a € 0.5 million round of grant funding from VLAIO (Flanders Innovation & Entrepreneurship), the research fund of the Flemish regional government in Belgium. During the three months ended July 31, 2024, the Company recorded € 0.1 million in grant income related to this funding.

Segmented Information and Econo

Segmented Information and Economic Dependence	3 Months Ended
	Jul. 31, 2024
Disclosure of operating segments [abstract]
SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE	14. SEGMENTED INFORMATION AND ECONOMIC DEPENDENCE At July 31, 2024 and April 30, 2024, the Company has one reportable segment, being antibody production and related services. The Company’s revenues are allocated to geographic regions for the three months ended July 31, 2024 and 2023 as follows: Three months ended (in thousands) 2024 2023 United States of America 2,966 2,433 Europe 2,258 2,965 Canada 16 126 Australia — 84 Other 23 80 5,263 5,688 The Company’s revenues are allocated according to revenue types for the three months ended July 31, 2024 and 2023 as follows: Three months ended (in thousands) 2024 2023 Project revenue 4,894 5,216 Product sales revenue 334 399 Cryostorage revenue 35 73 5,263 5,688 The Company’s non-current assets are allocated to geographic regions as of July 31, 2024 and April 30, 2024 as follows: July 31, April 30, North America - Corporate 80 80 North America 4,044 4,138 Belgium 22,184 22,261 Netherlands 21,972 22,022 48,280 48,501 Geographic segmentation of the Company’s net income (loss) for the three months ended July 31, 2024 and 2023 is as follows: Three months ended (in thousands) 2024 2023 North America - Corporate ( 2,587 ) ( 1,545 ) North America ( 126 ) ( 699 ) Belgium ( 1,604 ) ( 971 ) Netherlands 318 ( 201 ) ( 3,999 ) ( 3,416 ) Geographic segmentation of the interest and accretion, and amortization and depreciation for the three months ended July 31, 2024 and 2023 is as follows: Three months ended Interest and accretion (in thousands) 2024 2023 North America - Corporate 5 6 North America 57 32 Belgium 4 3 Netherlands 184 118 250 159 Three months ended Amortization and depreciation (in thousands) 2024 2023 North America - Corporate 2 3 North America 168 157 Belgium 522 605 Netherlands 703 729 1,395 1,494

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Jul. 31, 2024
Statement of cash flows [abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	15. SUPPLEMENTAL CASH FLOW INFORMATION Non-cash investing and financing transactions (in thousands) July 31, July 31, Acquisition of building and equipment by lease — 2,729 The following changes in liabilities arose from financing activities: Non-cash changes (in thousands) April 30, Cash Flows Acquisition Settlement Accretion Foreign July 31, Deferred acquisition payments 284 — — — 3 5 292 Leases 13,680 ( 394 ) — — — 215 13,501 Total 13,964 ( 394 ) — — 3 220 13,793 Non-cash changes (in thousands) April 30, Cash Flows Acquisition Debt forgiven Accretion Foreign July 31, Deferred acquisition payments 717 — — ( 146 ) 5 ( 17 ) 559 Leases 7,267 ( 405 ) 2,729 — — 224 9,815 Total 7,984 ( 405 ) 2,729 ( 146 ) 5 207 10,374

Subsequent Events

Subsequent Events	3 Months Ended
	Jul. 31, 2024
Disclosure of non-adjusting events after reporting period [abstract]
SUBSEQUENT EVENTS	16. SUBSEQUENT EVENTS On August 16, 2024, the Company completed the sale and issuance of the second tranche of U.S.$ 1.0 million principal amount of Convertible Debentures under the July 16, 2024 agreement with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP, under which the Company agreed to sell and issue to Yorkville U.S.$ 3.0 million aggregate principal amount of convertible debentures in two tranches and at a purchase price of 95 % of the aggregate principal amount. On August 19, 2024, the Company completed a conversion of $ 0.15 million of the principal amount of its Convertible Debentures, issued as part of the $ 1.0 million second tranche of the convertible debenture financing agreement with Yorkville, along with accrued interest. On August 27, 2024, the Company completed an additional conversion of $ 0.15 million of the principal amount of its Convertible Debenture, along with accrued interest. As a result of these transactions, the outstanding principal balance on the Convertible Debenture has been reduced by $ 0.3 million.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	3 Months Ended
	Jul. 31, 2024
Investments accounted for using equity method [abstract]
Summary of Subsidiaries which are Wholly Owned and Subject to Control	These condensed interim consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company: Name of Subsidiary % Equity Country of Functional Currency ImmunoPrecise Antibodies (Canada) Ltd. 100 % Canada Canadian dollar ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA") 100 % USA U.S. dollar ImmunoPrecise Antibodies (N.D.) Ltd. 100 % USA U.S. dollar ImmunoPrecise Antibodies (MA) LLC 100 % USA U.S. dollar Talem Therapeutics LLC ("Talem") 100 % USA U.S. dollar ImmunoPrecise Netherlands B.V. 100 % Netherlands Euro ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe") 100 % Netherlands Euro BioStrand B.V. 100 % Belgium Euro Idea Family B.V. 100 % Belgium Euro BioKey B.V. 100 % Belgium Euro BioClue B.V. 100 % Belgium Euro ImmunoPrecise Antibodies (Quebec), Ltd. 100 % Canada Canadian dollar 9438-9244 Quebec, Inc. 100 % Canada Canadian dollar
Summary of Effects of Adjustment on Financial Statements	The effects of this adjustment on our Consolidated Statements of Financial Position and Comprehensive Loss as of July 31, 2024 are as follows: Previously reported Adjustments As adjusted Balance sheet items: (in thousands) 4/30/2024 4/30/2024 4/30/2024 Deferred income tax liability 5,825 ( 1,758 ) 4,067 Total liabilities 26,067 ( 1,757 ) 24,310 Accumulated deficit ( 100,265 ) 1,705 ( 98,560 ) Accumulated other comprehensive loss 2,025 53 2,078 Total shareholders' equity 33,921 1,757 35,678 Previously reported Adjustments As adjusted Income statement items: (in thousands) 7/31/2023 7/31/2023 7/31/2023 Income taxes 262 153 415 Net loss for the period ( 3,565 ) 149 ( 3,416 ) Exchange difference on translating foreign operations ( 1,216 ) 46 ( 1,170 ) Comprehensive loss for the period ( 4,781 ) 195 ( 4,586 ) Basic and diluted loss per share* (0.14 ) 0.00 (0.14 ) * Because of the net loss, basic and diluted loss per share are the same given potential dilutive common shares are excluded from the computation as their effect would be anti-dilutive.

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Jul. 31, 2024
Disclosure of detailed information about property, plant and equipment [abstract]
Summary of Changes in the Value of Property and Equipment	The table below includes both property and equipment and right-of-use assets. (in thousands) Computer Furniture & Computer Building Automobile Leasehold Lab WIP - Total Cost: Balance, April 30, 2023 288 53 50 9,085 167 626 6,473 31 16,773 Additions 56 — — 7,826 1 27 1,316 — 9,226 Disposals ( 111 ) ( 31 ) ( 49 ) ( 1,634 ) — ( 344 ) ( 2,554 ) — ( 4,723 ) Foreign exchange ( 4 ) ( 1 ) ( 1 ) ( 133 ) ( 3 ) ( 2 ) ( 92 ) — ( 236 ) Balance, April 30, 2024 229 21 — 15,144 165 307 5,143 31 21,040 Additions — — — — — — 46 215 261 Foreign exchange 4 — — 242 3 2 78 — 329 Balance, July 31, 2024 233 21 — 15,386 168 309 5,267 246 21,630 Accumulated Depreciation: Balance, April 30, 2023 157 33 50 1,752 57 388 3,913 — 6,350 Depreciation 101 4 — 1,723 56 58 849 — 2,791 Disposals ( 110 ) ( 31 ) ( 49 ) ( 1,606 ) — ( 344 ) ( 2,554 ) — ( 4,694 ) Foreign exchange ( 2 ) — ( 1 ) ( 38 ) ( 1 ) — ( 61 ) — ( 103 ) Balance, April 30, 2024 146 6 — 1,831 112 102 2,147 — 4,344 Depreciation 25 1 — 473 14 15 255 — 783 Foreign exchange 3 ( 1 ) — 31 2 1 30 — 66 Balance, July 31, 2024 174 6 — 2,335 128 118 2,432 — 5,193 Net Book Value: April 30, 2024 83 15 — 13,313 53 205 2,996 31 16,696 July 31, 2024 59 15 — 13,051 40 191 2,835 246 16,437

Intangibles assets (Tables)

Intangibles assets (Tables)	3 Months Ended
	Jul. 31, 2024
Disclosure of detailed information about intangible assets [abstract]
Summary of Amortization for intangible assets with finite lives is provided over the following terms	Changes in the value of the intangible assets during the three months ended July 31, 2024 and the year ended April 30, 2024 are as follows: (in thousands) Internally Intellectual Proprietary Certifications Customer List Total Cost: Balance, April 30, 2023 33 35,143 8,103 139 198 43,616 Impairments and disposals — ( 3,830 ) ( 40 ) — ( 193 ) ( 4,063 ) Foreign exchange — ( 595 ) ( 137 ) ( 3 ) ( 5 ) ( 740 ) Balance, April 30, 2024 33 30,718 7,926 136 — 38,813 Foreign exchange — 641 166 3 — 810 Balance, July 31, 2024 33 31,359 8,092 139 — 39,623 Accumulated Amortization: Balance, April 30, 2023 14 4,775 7,633 136 132 12,690 Amortization 19 2,666 216 2 65 2,968 Disposals — — — — ( 193 ) ( 193 ) Foreign exchange — ( 74 ) ( 128 ) ( 2 ) ( 4 ) ( 208 ) Balance, April 30, 2024 33 7,367 7,721 136 — 15,257 Amortization — 589 17 — — 606 Foreign exchange — 170 163 3 — 336 Balance, July 31, 2024 33 8,126 7,901 139 — 16,199 Net Book Value: April 30, 2024 — 23,351 205 — — 23,556 July 31, 2024 — 23,233 191 — — 23,424

Leases (Tables)

Leases (Tables)	3 Months Ended
	Jul. 31, 2024
Presentation of leases for lessee [abstract]
Schedule of Future Minimum Lease Payments Related to Equipment under Finance Lease and Office Lease Obligation	Total cash outflow for leases during the three months ended July 31, 2024 wa s $ 0.4 million (2023 - $ 0.4 million). (in thousands) $ 2025 1,859 2026 2,452 2027 2,448 2028 2,442 2029 2,138 More than 5 years 5,836 Total minimum lease payments 17,175 Less: imputed interest ( 3,674 ) Total present value of minimum lease payments 13,501 Less: Current portion ( 1,605 ) Non-current portion 11,896
Schedule of Nature of Company's Leases Type of Right-of-Use Asset	The nature of the Company’s leases by type of right-of-use asset as at July 31, 2024 is as follows: Right-of-use assets Right-of-use asset type No. of right-of-use assets leased Range of remaining term Average remaining lease term No. of leases with extension options No. of leases with options to purchase No. of leases with variable payments linked to an index No. of leases with termination options Lab and office facilities 3 5.4 - 9.4 years 7.5 years 1 — 2 2 Automobiles 5 0.3 - 2.4 years .9 years — — 5 5
Schedule of Changes in the Value of Right-of-Use Assets	The changes in the value of right-of-use assets during the three months ended July 31, 2024 and the year ended April 30, 2024 are as follows: (in thousands) Building Automobile Total Cost: Balance, April 30, 2023 9,085 167 9,252 Additions 7,826 1 7,827 Disposals ( 1,634 ) — ( 1,634 ) Foreign exchange ( 133 ) ( 3 ) ( 136 ) Balance, April 30, 2024 15,144 165 15,309 Foreign exchange 242 3 245 Balance, July 31, 2024 15,386 168 15,554 Accumulated Depreciation: Balance, April 30, 2023 1,752 57 1,809 Depreciation 1,723 56 1,779 Disposals ( 1,606 ) — ( 1,606 ) Foreign exchange ( 37 ) ( 1 ) ( 38 ) Balance, April 30, 2024 1,832 112 1,944 Depreciation 473 14 487 Foreign exchange 31 3 34 Balance, July 31, 2024 2,336 129 2,465 Net Book Value: April 30, 2024 13,312 53 13,365 July 31, 2024 13,050 39 13,089
Schedule of Lease Payments Not Recognized Liability	The expense relating to payments not included in the measurement of the lease liability during the three months ended July 31, 2024 and 2023 are as follows: (in thousands) 2024 2023 Leases of low value assets 3 4 Variable lease payments 125 36 128 40

Share Capital (Tables)

Share Capital (Tables)	3 Months Ended
	Jul. 31, 2024
Disclosure of classes of share capital [abstract]
Summary of Stock Option Awards	The following table summarizes stock option awards during the three months ended July 31, 2024 and the year ended April 30, 2024, including the grant date fair value determined using the Black-Scholes option pricing model: Black-Scholes Option Pricing Model Inputs Grant date Stock options granted Exercisable price/option Awarded to Share price on grant date Dividend yield Expected volatility Risk-free rate Expected life Fair value January 19, 2024 (1) 240,000 1.48 Directors 1.48 (2) 0 % 77 % 3.64 % 5.0 years $ 0.4 million January 4, 2023 (1) 8,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 12 thousand January 23, 2023 (1) 8,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 12 thousand March 1, 2023 (1) 8,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 12 thousand March 15, 2023 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand April 2, 2023 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand May 8, 2023 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand May 23, 2023 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand June 11, 2023 (1) 8,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 12 thousand August 8, 2023 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand November 13, 2023 (1) 8,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 12 thousand January 1, 2024 (1) 12,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 18 thousand February 1, 2024 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand February 19, 2024 (1) 12,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 18 thousand February 20, 2024 (1) 4,000 1.47 Employees 1.47 (2) 0 % 77 % 3.68 % 10 years $ 6 thousand (1) Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date . (2) Priced in U.S.$
Summary of Changes in Stock Option	The changes in the stock options for the three months ended July 31, 2024 and the year ended April 30, 2024 are as follows: Number of Weighted Weighted Balance, April 30, 2023 (outstanding) 1,884,428 8.03 3.27 Granted 332,000 2.02 — Expired ( 577,335 ) 7.15 — Forfeited ( 117,726 ) 4.15 — Balance, April 30, 2024 (outstanding) 1,521,367 8.29 2.88 Expired ( 20,000 ) 14.50 — Forfeited ( 10,751 ) 1.45 — Balance, July 31, 2024 (outstanding) 1,490,616 7.14 3.19 Unvested ( 429,428 ) 3.39 4.84 Exercisable, July 31, 2024 1,061,188 8.66 2.53
Summary of Options Outstanding	Details of the options outstanding as at July 31, 2024 are as follows: Expiry Date Exercise Remaining Options Unvested Vested September 1, 2025 8.50 1.09 220,000 - 220,000 January 6, 2026 20.30 1.44 146,000 - 146,000 January 2, 2026 6.89 1.42 5,650 - 5,650 January 7, 2027 7.94 2.44 235,000 - 235,000 May 15, 2027 8.30 2.45 16,000 - 16,000 February 19, 2027 (1) 5.79 2.79 64,000 - 64,000 February 19, 2028 (1) 5.68 2.56 7,265 - 7,265 January 19, 2034 (2) 5.68 3.56 475,452 158,484 316,968 January 4, 2033 (3) 2.05 4.47 240,000 204,444 35,556 January 23, 2033 (3) 2.04 8.44 8,000 5,167 2,833 March 1, 2033 (3) 2.04 8.49 8,000 5,167 2,833 March 15, 2033 (3) 2.04 8.59 8,000 5,500 2,500 April 2, 2033 (3) 2.04 8.63 1,249 - 1,249 May 8, 2033 (3) 2.04 8.68 4,000 2,833 1,167 May 23, 2033 (3) 2.04 8.78 4,000 2,917 1,083 June 11, 2033 (3) 2.04 8.82 4,000 2,917 1,083 August 8, 2033 (3) 2.04 8.87 8,000 6,000 2,000 November 13, 2033 (3) 2.04 9.03 4,000 4,000 — January 1, 2034 (3) 2.04 9.29 8,000 8,000 — February 1, 2034 (3) 2.04 9.43 12,000 12,000 — February 19, 2034 (3) 2.04 9.51 4,000 4,000 — February 20, 2034 (3) 2.04 9.56 8,000 8,000 — 7.14 3.19 1,490,616 429,428 1,061,188 (1) Exercise price of U.S. $ 4.10 . The figure in the table above is translated at the July 31, 2024 rate. (2) Exercise price of U.S. $ 1.48 . The figure in the table above is translated at the July 31, 2024 rate. (3) Exercise price of U.S. $ 1.47 . The figure in the table above is translated at the July 31, 2024 rate.
Summary of Changes in Finder's Warrants	Details of the finder’s warrants outstanding as at July 31, 2024 are as follows: Number of Weighted average Weighted average life Balance, April 30, 2023 130,111 22.77 2.77 Issued 56,650 1.37 4.61 Balance, April 30, 2024 186,761 16.44 2.62 Exercised — — — Balance, July 31, 2024 186,761 16.63 2.38
Details of Finder's Warrants Outstanding	Details of the finder's warrants outstanding as at April 30, 2024 are as follows: Expiry Date Exercise price Remaining life Warrants February 3, 2026 (1) 23.27 1.51 130,111 December 8, 2028 (2) 1.38 4.37 56,650 (1) Exercise price of U.S. $ 16.81 . The figure in the table above is translated at the July 31, 2024 rate. (2) Exercise price of U.S. $ 1.00 . The figure in the table above is translated at the July 31, 2024 rate.

Employee Remuneration (Tables)

Employee Remuneration (Tables)	3 Months Ended
	Jul. 31, 2024
Disclosure of employee benefits expenses [abstract]
Summary of Expenses Recognized for Employee Benefits	Expenses recognized for employee benefits for the three months ended July 31, 2024 and 2023 are detailed below: (in thousands) 2024 2023 Wages, salaries 2,674 2,780 Employee benefits 210 340 Payroll taxes 200 181 Severance — 60 Share-based payments 165 823 3,249 4,184

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Jul. 31, 2024
Related party transactions [abstract]
Schedule of Schedule of Compensation For Key Management	(in thousands) 2024 2023 Salaries and other short-term benefits 613 647 Severance (included in salaries) — 60 Share-based payments 116 516 Director compensation (included in salaries) 84 71 813 1,294

Segmented Information and Eco_2

Segmented Information and Economic Dependence (Tables)	3 Months Ended
	Jul. 31, 2024
Disclosure of operating segments [abstract]
Summary of Geographical Segments	The Company’s revenues are allocated to geographic regions for the three months ended July 31, 2024 and 2023 as follows: Three months ended (in thousands) 2024 2023 United States of America 2,966 2,433 Europe 2,258 2,965 Canada 16 126 Australia — 84 Other 23 80 5,263 5,688 The Company’s non-current assets are allocated to geographic regions as of July 31, 2024 and April 30, 2024 as follows: July 31, April 30, North America - Corporate 80 80 North America 4,044 4,138 Belgium 22,184 22,261 Netherlands 21,972 22,022 48,280 48,501 Geographic segmentation of the Company’s net income (loss) for the three months ended July 31, 2024 and 2023 is as follows: Three months ended (in thousands) 2024 2023 North America - Corporate ( 2,587 ) ( 1,545 ) North America ( 126 ) ( 699 ) Belgium ( 1,604 ) ( 971 ) Netherlands 318 ( 201 ) ( 3,999 ) ( 3,416 ) Geographic segmentation of the interest and accretion, and amortization and depreciation for the three months ended July 31, 2024 and 2023 is as follows: Three months ended Interest and accretion (in thousands) 2024 2023 North America - Corporate 5 6 North America 57 32 Belgium 4 3 Netherlands 184 118 250 159 Three months ended Amortization and depreciation (in thousands) 2024 2023 North America - Corporate 2 3 North America 168 157 Belgium 522 605 Netherlands 703 729 1,395 1,494
Summary of Revenues Allocated According to Revenue Types	The Company’s revenues are allocated according to revenue types for the three months ended July 31, 2024 and 2023 as follows: Three months ended (in thousands) 2024 2023 Project revenue 4,894 5,216 Product sales revenue 334 399 Cryostorage revenue 35 73 5,263 5,688

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Jul. 31, 2024
Statement of cash flows [abstract]
Summary of Non-cash Investing and Financing Transactions	Non-cash investing and financing transactions (in thousands) July 31, July 31, Acquisition of building and equipment by lease — 2,729
Summary of Changes in Liabilities Arose From Financing Activities	The following changes in liabilities arose from financing activities: Non-cash changes (in thousands) April 30, Cash Flows Acquisition Settlement Accretion Foreign July 31, Deferred acquisition payments 284 — — — 3 5 292 Leases 13,680 ( 394 ) — — — 215 13,501 Total 13,964 ( 394 ) — — 3 220 13,793 Non-cash changes (in thousands) April 30, Cash Flows Acquisition Debt forgiven Accretion Foreign July 31, Deferred acquisition payments 717 — — ( 146 ) 5 ( 17 ) 559 Leases 7,267 ( 405 ) 2,729 — — 224 9,815 Total 7,984 ( 405 ) 2,729 ( 146 ) 5 207 10,374

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Jul. 31, 2024
Disclosure Of Income Taxes [Abstract]
Summary of Effects of Adjustment on Financial Statements	The effects of this adjustment on our Consolidated Statements of Financial Position and Comprehensive Loss as of July 31, 2024 are as follows: Previously reported Adjustments As adjusted Balance sheet items: (in thousands) 4/30/2024 4/30/2024 4/30/2024 Deferred income tax liability 5,825 ( 1,758 ) 4,067 Total liabilities 26,067 ( 1,757 ) 24,310 Accumulated deficit ( 100,265 ) 1,705 ( 98,560 ) Accumulated other comprehensive loss 2,025 53 2,078 Total shareholders' equity 33,921 1,757 35,678 Previously reported Adjustments As adjusted Income statement items: (in thousands) 7/31/2023 7/31/2023 7/31/2023 Income taxes 262 153 415 Net loss for the period ( 3,565 ) 149 ( 3,416 ) Exchange difference on translating foreign operations ( 1,216 ) 46 ( 1,170 ) Comprehensive loss for the period ( 4,781 ) 195 ( 4,586 ) Basic and diluted loss per share* (0.14 ) 0.00 (0.14 ) * Because of the net loss, basic and diluted loss per share are the same given potential dilutive common shares are excluded from the computation as their effect would be anti-dilutive.

Nature of Operations - Addition

Nature of Operations - Additional Information (Details) - CAD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Apr. 30, 2024
Disclosure Of Nature Of Operations [Abstract]
Operating losses	$ 3,999	$ 3,416
Accumulated deficit	$ 102,559		$ 98,560

Basis of Presentation - Summary

Basis of Presentation - Summary of Subsidiaries which are Wholly Owned and Subject to Control (Details)	3 Months Ended
	Jul. 31, 2024
ImmunoPrecise Antibodies (Canada) Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (Canada) Ltd.
Equity Interest percentage	100%
Country of Incorporation	Canada
Functional Currency	Canadian dollar
ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA")
Equity Interest percentage	100%
Country of Incorporation	USA
Functional Currency	U.S. dollar
ImmunoPrecise Antibodies (N.D.) Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (N.D.) Ltd.
Equity Interest percentage	100%
Country of Incorporation	USA
Functional Currency	U.S. dollar
ImmunoPrecise Antibodies (MA) LLC
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (MA) LLC
Equity Interest percentage	100%
Country of Incorporation	USA
Functional Currency	U.S. dollar
Talem Therapeutics LLC ("Talem")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	Talem Therapeutics LLC ("Talem")
Equity Interest percentage	100%
Country of Incorporation	USA
Functional Currency	U.S. dollar
ImmunoPrecise Netherlands B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Netherlands B.V.
Equity Interest percentage	100%
Country of Incorporation	Netherlands
Functional Currency	Euro
ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe")
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe")
Equity Interest percentage	100%
Country of Incorporation	Netherlands
Functional Currency	Euro
BioStrand B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	BioStrand B.V.
Equity Interest percentage	100%
Country of Incorporation	Belgium
Functional Currency	Euro
Idea Family B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	Idea Family B.V.
Equity Interest percentage	100%
Country of Incorporation	Belgium
Functional Currency	Euro
BioKey B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	BioKey B.V.
Equity Interest percentage	100%
Country of Incorporation	Belgium
Functional Currency	Euro
BioClue B.V.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	BioClue B.V.
Equity Interest percentage	100%
Country of Incorporation	Belgium
Functional Currency	Euro
ImmunoPrecise Antibodies (Quebec), Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	ImmunoPrecise Antibodies (Quebec), Ltd.
Equity Interest percentage	100%
Country of Incorporation	Canada
Functional Currency	Canadian dollar
9438-9244 Quebec, Inc
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Subsidiary	9438-9244 Quebec, Inc.
Equity Interest percentage	100%
Country of Incorporation	Canada
Functional Currency	Canadian dollar

Basis of Presentation - Summa_2

Basis of Presentation - Summary of Effects of Adjustment on Consolidated Balance Sheet (Details) - CAD ($) $ in Thousands	Jul. 31, 2024	Apr. 30, 2024	Jul. 31, 2023	Apr. 30, 2023
Statement Of Balance Sheet [line items]
Deferred income tax liability	$ 3,376	$ 4,067
Total liabilities	26,445	24,310
Accumulated deficit	(102,559)	(98,560)
Accumulated other comprehensive loss	2,597	2,078
Total shareholders' equity	$ 32,854	35,678	$ 54,752	$ 58,515
Previously stated [member]
Statement Of Balance Sheet [line items]
Deferred income tax liability		5,825
Total liabilities		26,067
Accumulated deficit		(100,265)
Accumulated other comprehensive loss		2,025
Total shareholders' equity		33,921
Adjustments
Statement Of Balance Sheet [line items]
Deferred income tax liability		(1,758)
Total liabilities		(1,757)
Accumulated deficit		1,705
Accumulated other comprehensive loss		53
Total shareholders' equity		$ 1,757

Basis of Presentation - Summa_3

Basis of Presentation - Summary of Effects of Adjustment on Income Statement (Details) - CAD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Income Statement [line items]
Income taxes	$ 776	$ 415
Net loss for the period	(3,999)	(3,416)
Exchange difference on translating foreign operations	519	(1,170)
Comprehensive loss for the period	$ (3,480)	(4,586)
Previously Reported
Income Statement [line items]
Income taxes		262
Net loss for the period		(3,565)
Exchange difference on translating foreign operations		(1,216)
Comprehensive loss for the period		(4,781)
Adjustments
Income Statement [line items]
Income taxes		153
Net loss for the period		149
Exchange difference on translating foreign operations		46
Comprehensive loss for the period		$ 195

Property and Equipment - Summar

Property and Equipment - Summary of Changes in the Value of Property and Equipment (Details) - CAD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jul. 31, 2024	Apr. 30, 2024
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	$ 16,696
Ending balance	16,437	$ 16,696
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	21,040	16,773
Additions	261	9,226
Disposals		(4,723)
Foreign exchange	329	(236)
Ending balance	21,630	21,040
Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(4,344)	(6,350)
Depreciation	783	2,791
Disposals		4,694
Foreign exchange	66	(103)
Ending balance	(5,193)	(4,344)
Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	16,696
Ending balance	16,437	16,696
Computer Hardware | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	229	288
Additions	0	56
Disposals		(111)
Foreign exchange	4	(4)
Ending balance	233	229
Computer Hardware | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(146)	(157)
Depreciation	25	101
Disposals		110
Foreign exchange	3	(2)
Ending balance	(174)	(146)
Computer Hardware | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	83
Ending balance	59	83
Furniture and Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	21	53
Additions	0	0
Disposals		(31)
Foreign exchange	0	(1)
Ending balance	21	21
Furniture and Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(6)	(33)
Depreciation	1	4
Disposals		31
Foreign exchange	(1)	0
Ending balance	(6)	(6)
Furniture and Equipment | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	15
Ending balance	15	15
Computer Software | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	0	50
Additions	0	0
Disposals		(49)
Foreign exchange	0	(1)
Ending balance	0	0
Computer Software | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	0	(50)
Depreciation	0	0
Disposals		49
Foreign exchange	0	(1)
Ending balance	0	0
Computer Software | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	0
Ending balance	0	0
Building | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	15,144	9,085
Additions	0	7,826
Disposals		(1,634)
Foreign exchange	242	(133)
Ending balance	15,386	15,144
Building | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(1,831)	(1,752)
Depreciation	473	1,723
Disposals		1,606
Foreign exchange	31	(38)
Ending balance	(2,335)	(1,831)
Building | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	13,313
Ending balance	13,051	13,313
Automobile | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	165	167
Additions	0	1
Disposals		0
Foreign exchange	3	(3)
Ending balance	168	165
Automobile | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(112)	(57)
Depreciation	14	56
Disposals		0
Foreign exchange	2	(1)
Ending balance	(128)	(112)
Automobile | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	53
Ending balance	40	53
Leasehold Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	307	626
Additions	0	27
Disposals		(344)
Foreign exchange	2	(2)
Ending balance	309	307
Leasehold Improvements | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(102)	(388)
Depreciation	15	58
Disposals		344
Foreign exchange	1	0
Ending balance	(118)	(102)
Leasehold Improvements | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	205
Ending balance	191	205
Lab Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	5,143	6,473
Additions	46	1,316
Disposals		(2,554)
Foreign exchange	78	(92)
Ending balance	5,267	5,143
Lab Equipment | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(2,147)	(3,913)
Depreciation	255	849
Disposals		2,554
Foreign exchange	30	(61)
Ending balance	(2,432)	(2,147)
Lab Equipment | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	2,996
Ending balance	2,835	2,996
WIP - Leasehold Improvements | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	31	31
Additions	215	0
Disposals		0
Foreign exchange	0	0
Ending balance	246	31
WIP - Leasehold Improvements | Accumulated Depreciation
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	0	0
Depreciation	0	0
Disposals		0
Foreign exchange	0	0
Ending balance	0	0
WIP - Leasehold Improvements | Net Book Value
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	31
Ending balance	$ 246	$ 31

Intangibles Assets - Summary of

Intangibles Assets - Summary of Changes in the Value of the Intangible Assets (Details) - CAD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jul. 31, 2024	Apr. 30, 2024
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 23,557
Ending balance	23,424	$ 23,557
Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	38,813	43,616
Impairments and disposals		(4,063)
Foreign exchange	810	(740)
Ending balance	39,623	38,813
Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	15,257	12,690
Amortization	606	2,968
Disposals		(193)
Foreign exchange	336	(208)
Ending balance	16,199	15,257
Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	23,556
Ending balance	23,424	23,556
Internally Generated Development Costs | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	33	33
Impairments and disposals		0
Foreign exchange	0	0
Ending balance	33	33
Internally Generated Development Costs | Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	33	14
Amortization	0	19
Disposals		0
Foreign exchange	0	0
Ending balance	33	33
Internally Generated Development Costs | Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Ending balance	0	0
Intellectual Properties | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	30,718	35,143
Impairments and disposals		(3,830)
Foreign exchange	641	(595)
Ending balance	31,359	30,718
Intellectual Properties | Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	7,367	4,775
Amortization	589	2,666
Disposals		0
Foreign exchange	170	(74)
Ending balance	8,126	7,367
Intellectual Properties | Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	23,351
Ending balance	23,233	23,351
Proprietary Processes | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	7,926	8,103
Impairments and disposals		(40)
Foreign exchange	166	(137)
Ending balance	8,092	7,926
Proprietary Processes | Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	7,721	7,633
Amortization	17	216
Disposals		0
Foreign exchange	163	(128)
Ending balance	7,901	7,721
Proprietary Processes | Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	205
Ending balance	191	205
Certifications | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	136	139
Impairments and disposals		0
Foreign exchange	3	(3)
Ending balance	139	136
Certifications | Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	136	136
Amortization	0	2
Disposals		0
Foreign exchange	3	(2)
Ending balance	139	136
Certifications | Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Ending balance	0	0
Customer List | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	198
Impairments and disposals		(193)
Foreign exchange	0	(5)
Ending balance	0	0
Customer List | Accumulated Amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0	132
Amortization	0	65
Disposals		(193)
Foreign exchange	0	(4)
Ending balance	0	0
Customer List | Net Book Value
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Ending balance	$ 0	$ 0

Convertible Debentures - Additi

Convertible Debentures - Additional Information (Details) - YA II PN, Ltd. - Convertible Debentures $ in Millions	Jul. 16, 2024 USD ($)
Convertible Debentures [Line Items]
Aggregate principal amount of convertible debentures agreed to sell and issue	$ 3
Percentage of purchase price to aggregate principal amount	95%
Convertible debentures interest rate	8%
Tranche One
Convertible Debentures [Line Items]
Aggregate principal amount of convertible debentures agreed to sell and issue	$ 2
Tranche Two
Convertible Debentures [Line Items]
Aggregate principal amount of convertible debentures agreed to sell and issue	$ 1

Leases - Additional Information

Leases - Additional Information (Details) - CAD ($) $ in Millions	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Presentation of leases for lessee [abstract]
Cash outflow for leases	$ 0.4	$ 0.4

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments Related to Equipment under Finance Lease and Office Lease Obligation (Details) $ in Thousands	Jul. 31, 2024 CAD ($)
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	$ 17,175
Less: imputed interest	(3,674)
Total present value of minimum lease payments	13,501
Less: Current portion	(1,605)
Non-current portion	11,896
2025
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	1,859
2026
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	2,452
2027
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	2,448
2028
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	2,442
2029
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	2,138
More than 5 years
Disclosure Of Maturity Analysis Of Finance And Office Lease Payments [Line Items]
Total minimum lease payments	$ 5,836

Leases - Schedule of Disclosure

Leases - Schedule of Disclosure in Tabular Form of Nature of Companies Leases (Detail)	3 Months Ended
	Jul. 31, 2024
Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Number of right of use assets leased	3
No. of leases with extension options	1
No. of leases with options to purchase	0
No. of leases with variable payments linked to an index	2
No. of leases with termination options	2
Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Number of right of use assets leased	5
No. of leases with extension options	0
No. of leases with options to purchase	0
No. of leases with variable payments linked to an index	5
No. of leases with termination options	5
Weighted average | Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	7 years 6 months
Weighted average | Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	10 months 24 days
Bottom of Range | Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	5 years 4 months 24 days
Bottom of Range | Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	3 months 18 days
Top of Range | Lab and office facilities
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	9 years 4 months 24 days
Top of Range | Automobile
Disclosure In Tabular Form Of Nature Of Companies Leases [Line Items]
Range of remaining term	2 years 4 months 24 days

Leases - Schedule of Changes in

Leases - Schedule of Changes in the Value of the Right-of-Use Assets (Details) - CAD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jul. 31, 2024	Apr. 30, 2024
Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	$ 15,309	$ 9,252
Additions		7,827
Disposals		(1,634)
Foreign exchange	245	(136)
Ending balance	15,554	15,309
Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	1,944	1,809
Depreciation	487	1,779
Disposals		(1,606)
Foreign exchange	34	(38)
Ending balance	2,465	1,944
Net Book Value
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	13,365
Ending balance	13,089	13,365
Building | Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	15,144	9,085
Additions		7,826
Disposals		(1,634)
Foreign exchange	242	(133)
Ending balance	15,386	15,144
Building | Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	1,832	1,752
Depreciation	473	1,723
Disposals		(1,606)
Foreign exchange	31	(37)
Ending balance	2,336	1,832
Building | Net Book Value
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	13,312
Ending balance	13,050	13,312
Automobile | Cost
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	165	167
Additions		1
Foreign exchange	3	(3)
Ending balance	168	165
Automobile | Accumulated Depreciation
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	112	57
Depreciation	14	56
Foreign exchange	3	(1)
Ending balance	129	112
Automobile | Net Book Value
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	53
Ending balance	$ 39	$ 53

Leases - Schedule of Disclosu_2

Leases - Schedule of Disclosure in Tabular Form Of Expenses Relating to Payments not included (Detail) - CAD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Presentation of leases for lessee [abstract]
Leases of low value assets	$ 3	$ 4
Variable lease payments	125	36
Measurement of the lease liability	$ 128	$ 40

Share Capital - Additional Info

Share Capital - Additional Information (Details) $ / shares in Units, $ in Thousands, $ in Millions			3 Months Ended			12 Months Ended
	Jul. 29, 2024 USD ($)	Feb. 23, 2024 USD ($)	Jul. 31, 2024 CAD ($)	Jul. 26, 2024 CAD ($) shares	Jul. 31, 2023 CAD ($)	Apr. 30, 2024 CAD ($) shares	Apr. 30, 2024 $ / shares shares
Disclosure Of Classes Of Share Capital [Line Items]
Share-based payments | $			$ 165		$ 823
Number of underwritten public offering shares | shares						1,265,000
Number of shares exercise by underwriter of over allotment option | shares						165,000
Public offering price for each common share | $ / shares							$ 1
Number of common shares sold | shares				357,760			629,240
Proceeds from sale of common shares | $				$ 500		$ 1,800
At The Market Equity Offering Facility | Top of Range
Disclosure Of Classes Of Share Capital [Line Items]
Common stock aggregate gross sales price | $	$ 8.8	$ 60

Share Capital - Summary of Stoc

Share Capital - Summary of Stock Option Awards (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Jul. 31, 2024 CAD ($) yr shares $ / shares	[1]
January 19, 2024 | Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	January 19, 2024
Stock options granted | shares	240,000
Exercisable price/option	$ 1.48
Awarded to	Directors
Share price on grant date	$ 1.48	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.64%
Expected life | yr	5
Fair value | $	$ 400
January 4, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	January 4, 2023
Stock options granted | shares	8,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 12
January 23, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	January 23, 2023
Stock options granted | shares	8,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 12
March 1, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	March 1, 2023
Stock options granted | shares	8,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 12
March 15, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	March 15, 2023
Stock options granted | shares	4,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 6
April 2, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	April 2, 2023
Stock options granted | shares	4,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 6
May 8, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	May 8, 2023
Stock options granted | shares	4,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 6
May 23, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	May 23, 2023
Stock options granted | shares	4,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 6
June 11, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	June 11, 2023
Stock options granted | shares	8,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 12
August 8, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	August 8, 2023
Stock options granted | shares	4,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 6
November 13, 2023 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	November 13, 2023
Stock options granted | shares	8,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 12
January 1, 2024 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	January 1, 2024
Stock options granted | shares	12,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 18
February 1, 2024 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	February 1, 2024
Stock options granted | shares	4,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 6
February 19, 2024 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	February 19, 2024
Stock options granted | shares	12,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 18
February 20, 2024 | Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	February 20, 2024
Stock options granted | shares	4,000
Exercisable price/option	$ 1.47
Awarded to	Employees
Share price on grant date	$ 1.47	[2]
Dividend yield	0%
Expected volatility	77%
Risk- free rate	3.68%
Expected life | yr	10
Fair value | $	$ 6
[1] Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date . Priced in U.S.$

Share Capital - Summary of St_2

Share Capital - Summary of Stock Option Awards (Parenthetical) (Details)	3 Months Ended
	Jul. 31, 2024
January 19, 2024 | Director [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
January 4, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
January 23, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
March 1, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
March 15, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
April 2, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
May 8, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
May 23, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date.
June 11, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
August 8, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
November 13, 2023 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
January 1, 2024 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
February 1, 2024 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
February 19, 2024 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date
February 20, 2024 | Employees [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Description of vesting requirements for share-based payment arrangement	Vesting conditions are as follows: one-fourth one year from hire date; one thirty-sixth each month after hire date

Share Capital - Summary of Chan

Share Capital - Summary of Changes in Stock Option (Details)	3 Months Ended	12 Months Ended
	Jul. 31, 2024 shares $ / shares	Apr. 30, 2024 shares $ / shares	Apr. 30, 2023 shares $ / shares
Disclosure of classes of share capital [abstract]
Number of options, Outstanding, Beginning balance | shares	1,521,367	1,884,428
Number of options, Granted | shares		332,000
Number of option, Expired | shares	(20,000)	(577,335)
Number of options, Forfeited | shares	(10,751)	(117,726)
Number of options, Outstanding | shares	1,490,616	1,521,367	1,884,428
Number of options, Unvested | shares	(429,428)
Number of options, Exercisable | shares	1,061,188
Weighted average exercise price outstanding, Beginning balance | $ / shares	$ 8.29	$ 8.03
Weighted average exercise price, Granted | $ / shares		2.02
Weighted average exercise price, Expired | $ / shares	14.5	7.15
Weighted average exercise price, Forfeited | $ / shares	1.45	4.15
Weighted average exercise price outstanding, Ending balance | $ / shares	7.14	$ 8.29	$ 8.03
Weighted average exercise price, Unvested | $ / shares	3.39
Weighted average exercise price, Exercisable | $ / shares	$ 8.66
Weighted average life remaining (years)	3 years 2 months 8 days	2 years 10 months 17 days	3 years 3 months 7 days
Weighted average life remaining (years), Unvested	4 years 10 months 2 days
Weighted average life remaining (years), Exercisable	2 years 6 months 10 days

Share Capital - Summary of Opti

Share Capital - Summary of Options Outstanding (Details)		3 Months Ended
		Jul. 31, 2024 shares $ / shares		Jul. 31, 2024 shares $ / shares	Apr. 30, 2024 shares	Apr. 30, 2023 shares
Disclosure Of Classes Of Share Capital [Line Items]
Exercise price | $ / shares		$ 7.14
Remaining life (year)		3 years 2 months 8 days
Options outstanding		1,490,616		1,490,616	1,521,367	1,884,428
Unvested		429,428		429,428
Vested		1,061,188		1,061,188
Option Expiry Date September 1, 2025
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		September 1, 2025
Exercise price | $ / shares		$ 8.5
Remaining life (year)		1 year 1 month 2 days
Options outstanding		220,000		220,000
Unvested		0		0
Vested		220,000		220,000
Option Expiry Date January 6, 2026
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 6, 2026
Exercise price | $ / shares		$ 20.3
Remaining life (year)		1 year 5 months 8 days
Options outstanding		146,000		146,000
Unvested		0		0
Vested		146,000		146,000
Option Expiry Date January 2, 2026
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 2, 2026
Exercise price | $ / shares		$ 6.89
Remaining life (year)		1 year 5 months 1 day
Options outstanding		5,650		5,650
Unvested		0		0
Vested		5,650		5,650
Option Expiry Date January 7, 2027
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		January 7, 2027
Exercise price | $ / shares		$ 7.94
Remaining life (year)		2 years 5 months 8 days
Options outstanding		235,000		235,000
Unvested		0		0
Vested		235,000		235,000
Option Expiry Date May 15, 2027
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date		May 15, 2027
Exercise price | $ / shares		$ 8.3
Remaining life (year)		2 years 5 months 12 days
Options outstanding		16,000		16,000
Unvested		0		0
Vested		16,000		16,000
Option Expiry Date February 19, 2027
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[1]	February 19, 2027
Exercise price | $ / shares	[1]	$ 5.79
Remaining life (year)	[1]	2 years 9 months 14 days
Options outstanding	[1]	64,000		64,000
Unvested	[1]	0		0
Vested	[1]	64,000		64,000
Option Expiry Date February 19, 2028
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[1]	February 19, 2028
Exercise price | $ / shares	[1]	$ 5.68
Remaining life (year)	[1]	2 years 6 months 21 days
Options outstanding	[1]	7,265		7,265
Unvested	[1]	0		0
Vested	[1]	7,265		7,265
Option Expiry Date January 19, 2034
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[2]	January 19, 2034
Exercise price | (per share)		$ 5.68	[2]	$ 1.48
Remaining life (year)	[2]	3 years 6 months 21 days
Options outstanding	[2]	475,452		475,452
Unvested	[2]	158,484		158,484
Vested	[2]	316,968		316,968
Option Expiry Date January 4, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	January 4, 2033
Exercise price | $ / shares	[3]	$ 2.05
Remaining life (year)	[3]	4 years 5 months 19 days
Options outstanding	[3]	240,000		240,000
Unvested	[3]	204,444		204,444
Vested	[3]	35,556		35,556
Option Expiry Date January 23, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	January 23, 2033
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	8 years 5 months 8 days
Options outstanding	[3]	8,000		8,000
Unvested	[3]	5,167		5,167
Vested	[3]	2,833		2,833
Option Expiry Date March 1, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	March 1, 2033
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	8 years 5 months 26 days
Options outstanding	[3]	8,000		8,000
Unvested	[3]	5,167		5,167
Vested	[3]	2,833		2,833
Option Expiry Date March 15, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	March 15, 2033
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	8 years 7 months 2 days
Options outstanding	[3]	8,000		8,000
Unvested	[3]	5,500		5,500
Vested	[3]	2,500		2,500
Option Expiry Date April 2, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	April 2, 2033
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	8 years 7 months 17 days
Options outstanding	[3]	1,249		1,249
Vested	[3]	1,249		1,249
Option Expiry Date May 8, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	May 8, 2033
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	8 years 8 months 4 days
Options outstanding	[3]	4,000		4,000
Unvested	[3]	2,833		2,833
Vested	[3]	1,167		1,167
Option Expiry Date May 23, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	May 23, 2033
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	8 years 9 months 10 days
Options outstanding	[3]	4,000		4,000
Unvested	[3]	2,917		2,917
Vested	[3]	1,083		1,083
Option Expiry Date June 11, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	June 11, 2033
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	8 years 9 months 25 days
Options outstanding	[3]	4,000		4,000
Unvested	[3]	2,917		2,917
Vested	[3]	1,083		1,083
Option Expiry Date August 8, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	August 8, 2033
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	8 years 10 months 13 days
Options outstanding	[3]	8,000		8,000
Unvested	[3]	6,000		6,000
Vested	[3]	2,000		2,000
Option Expiry Date November 13, 2033
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	November 13, 2033
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	9 years 10 days
Options outstanding	[3]	4,000		4,000
Unvested	[3]	4,000		4,000
Vested	[3]	0		0
Option Expiry Date January 1, 2034
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	January 1, 2034
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	9 years 3 months 14 days
Options outstanding	[3]	8,000		8,000
Unvested	[3]	8,000		8,000
Vested	[3]	0		0
Option Expiry Date February 1, 2034
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	February 1, 2034
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	9 years 5 months 4 days
Options outstanding	[3]	12,000		12,000
Unvested	[3]	12,000		12,000
Vested	[3]	0		0
Option Expiry Date February 19, 2034
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	February 19, 2034
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	9 years 6 months 3 days
Options outstanding	[3]	4,000		4,000
Unvested	[3]	4,000		4,000
Vested	[3]	0		0
Option Expiry Date February 20, 2034
Disclosure Of Classes Of Share Capital [Line Items]
Expiry Date	[3]	February 20, 2034
Exercise price | $ / shares	[3]	$ 2.04
Remaining life (year)	[3]	9 years 6 months 21 days
Options outstanding	[3]	8,000		8,000
Unvested	[3]	8,000		8,000
Vested	[3]	0		0
[1] Exercise price of U.S. $ 4.10 . The figure in the table above is translated at the July 31, 2024 rate. Exercise price of U.S. $ 1.48 . The figure in the table above is translated at the July 31, 2024 rate. Exercise price of U.S. $ 1.47 . The figure in the table above is translated at the July 31, 2024 rate.

Share Capital - Summary of Op_2

Share Capital - Summary of Options Outstanding (Parenthetical) (Details) - Jul. 31, 2024	$ / shares		$ / shares
Disclosure of classes of share capital [line items]
Exercise price	$ 7.14
Option 6 and 7
Disclosure of classes of share capital [line items]
Exercise price			$ 4.1
Option 8
Disclosure of classes of share capital [line items]
Exercise price | (per share)	$ 5.68	[1]	1.48
Option 9 to 22
Disclosure of classes of share capital [line items]
Exercise price			$ 1.47
[1] Exercise price of U.S. $ 1.48 . The figure in the table above is translated at the July 31, 2024 rate.

Share Capital - Summary of Ch_2

Share Capital - Summary of Changes in Finder's Warrants (Details) - Finder's Warrants	3 Months Ended	12 Months Ended
	Jul. 31, 2024 shares $ / shares	Apr. 30, 2024 shares $ / shares	Apr. 30, 2023 shares $ / shares
Disclosure Of Classes Of Share Capital [Line Items]
Balance, Number of warrants | shares	186,761	130,111
Issued, Number of warrants | shares		56,650
Exercised, Number of warrants | shares	0
Balance, Number of warrants | shares	186,761	186,761	130,111
Balance, Weighted average exercise price | $ / shares	$ 16.44	$ 22.77
Issued, Weighted average exercise price | $ / shares		1.37
Exercised, Weighted average exercise price | $ / shares	0
Balance, Weighted average exercise price | $ / shares	$ 16.63	$ 16.44	$ 22.77
Weighted average life remaining, Issued (years)		4 years 7 months 9 days
Weighted average life remaining (years)	2 years 4 months 17 days	2 years 7 months 13 days	2 years 9 months 7 days

Share Capital - Details of Find

Share Capital - Details of Finder's Warrants Outstanding (Details) - Finder's Warrants		12 Months Ended
		Apr. 30, 2024 shares $ / shares	Jul. 31, 2024 shares	Apr. 30, 2023 shares
Disclosure of classes of share capital [line items]
Warrants outstanding		186,761	186,761	130,111
Range One
Disclosure of classes of share capital [line items]
Expiry Date	[1]	Feb. 03, 2026
Exercise price $ | $ / shares	[1]	$ 23.27
Remaining life (year)	[1]	1 year 6 months 3 days
Warrants outstanding	[1]	130,111
Range Two
Disclosure of classes of share capital [line items]
Expiry Date	[2]	Dec. 08, 2028
Exercise price $ | $ / shares	[2]	$ 1.38
Remaining life (year)	[2]	4 years 4 months 13 days
Warrants outstanding	[2]	56,650
[1] Exercise price of U.S. $ 16.81 . The figure in the table above is translated at the July 31, 2024 rate. Exercise price of U.S. $ 1.00 . The figure in the table above is translated at the July 31, 2024 rate.

Share Capital - Details of Fi_2

Share Capital - Details of Finder's Warrants Outstanding (Parenthetical) (Details) - Finder's Warrants	3 Months Ended
	Jul. 31, 2024 $ / shares
Range One
Disclosure Of Classes Of Share Capital [Line Items]
Warrant exercisable price	$ 16.81
Range Two
Disclosure Of Classes Of Share Capital [Line Items]
Warrant exercisable price	$ 1

Employee Remuneration - Summary

Employee Remuneration - Summary of Expenses Recognized for Employee Benefits (Details) - CAD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Disclosure of employee benefits expenses [abstract]
Wages, salaries	$ 2,674	$ 2,780
Employee benefits	210	340
Payroll taxes	200	181
Severance	0	60
Share-based payments	165	823
Total employee benefits expense	$ 3,249	$ 4,184

Related Party Transactions - Sc

Related Party Transactions - Schedule of Compensation For Key Management (Details) - CAD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Disclosure of transactions between related parties [abstract]
Salaries and other short-term benefits	$ 613	$ 647
Severance (included in salaries)	0	60
Share-based payments	116	516
Director compensation (included in salaries)	84	71
Related party transaction, due from (to) related party	$ 813	$ 1,294

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - CAD ($) $ in Millions	Jul. 31, 2024	Apr. 30, 2023
Related party transactions [abstract]
Accrued liabilities related parties current	$ 0.3	$ 1.2

Commitments - Additional Inform

Commitments - Additional Information (Details) € in Millions	3 Months Ended
	Jul. 31, 2024 EUR (€)
Commitments [Line Items]
Minimum contingent earnout payment	€ 12
BioStrand [Member]
Commitments [Line Items]
Percentage of contingent earnout payment based on EBITDA	20%
Unpaid commitment related to earnout	€ 12

Grant and Subsidy Income - Addi

Grant and Subsidy Income - Additional Information (Details) $ in Thousands, € in Millions	3 Months Ended
	Jul. 31, 2024 CAD ($)	Jul. 31, 2024 EUR (€)	Jul. 31, 2023 CAD ($)	May 31, 2022 EUR (€)
Grant And Subsidy Income [Abstract]
Grant awarded				€ 0.5
Grant income	$ 146	€ 0.1	$ 283

Inventories - Summary of Detail

Inventories - Summary of Detailed Information About Inventories (Detail) - CAD ($) $ in Thousands	Jul. 31, 2024	Apr. 30, 2024
Classes of current inventories [abstract]
Inventories	$ 1,869	$ 2,139

Segmented Information and Eco_3

Segmented Information and Economic Dependence - Summary of Geographical Segments (Details) - CAD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023	Apr. 30, 2023
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 5,263	$ 5,688
Non-current assets		48,280	$ 48,501
Net income (loss)	(3,999)	(3,416)
Interest and accretion	250	159
Amortization and depreciation	1,395	1,494
United States of America
Disclosure Of Geographical Areas [Line Items]
Revenues	2,966	2,433
Europe
Disclosure Of Geographical Areas [Line Items]
Revenues	2,258	2,965
Canada
Disclosure Of Geographical Areas [Line Items]
Revenues	16	126
Australia
Disclosure Of Geographical Areas [Line Items]
Revenues	0	84
North America
Disclosure Of Geographical Areas [Line Items]
Non-current assets		4,044	4,138
Net income (loss)	(126)	(699)
Interest and accretion	57	32
Amortization and depreciation	168	157
North America | Corporate
Disclosure Of Geographical Areas [Line Items]
Non-current assets		80	80
Net income (loss)	(2,587)	(1,545)
Interest and accretion	5	6
Amortization and depreciation	2	3
Belgium
Disclosure Of Geographical Areas [Line Items]
Non-current assets		22,184	22,261
Net income (loss)	(1,604)	(971)
Interest and accretion	4	3
Amortization and depreciation	522	605
Netherlands
Disclosure Of Geographical Areas [Line Items]
Non-current assets		21,972	$ 22,022
Net income (loss)	318	(201)
Interest and accretion	184	118
Amortization and depreciation	703	729
Other
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 23	$ 80

Segmented Information and Eco_4

Segmented Information and Economic Dependence - Summary of Revenues Allocated According to Revenue Types (Details) - CAD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 5,263	$ 5,688
Project Revenue
Disclosure Of Geographical Areas [Line Items]
Revenues	4,894	5,216
Product Sales Revenue
Disclosure Of Geographical Areas [Line Items]
Revenues	334	399
Cryo Storage Revenue
Disclosure Of Geographical Areas [Line Items]
Revenues	$ 35	$ 73

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Summary of Non-cash Investing and Financing Transactions (Details) - CAD ($) $ in Thousands	Jul. 31, 2024	Jul. 31, 2023
Statements [Line Items]
Acquisition of building and equipment by lease	$ 0	$ 2,729

Supplemental Cash Flow Inform_4

Supplemental Cash Flow Information - Summary of Changes in Liabilities Arose From Financing Activities (Details) - CAD ($) $ in Thousands	3 Months Ended
	Jul. 31, 2024	Jul. 31, 2023
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	$ 13,964	$ 7,984
Cash Flows	(394)	(405)
Non-cash changes, Acquisition	0	2,729
Non-cash changes, Debt forgiven/ Settlement/ Disposal	0	(146)
Non-cash changes, Accretion	3	5
Non-cash changes, Foreign exchange movements and change in estimates	220	207
Ending balance	13,793	10,374
Deferred Acquisition Payments
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	284	717
Cash Flows	0	0
Non-cash changes, Acquisition	0	0
Non-cash changes, Debt forgiven/ Settlement/ Disposal	0	(146)
Non-cash changes, Accretion	3	5
Non-cash changes, Foreign exchange movements and change in estimates	5	(17)
Ending balance	292	559
Leases
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	13,680	7,267
Cash Flows	(394)	(405)
Non-cash changes, Acquisition	0	2,729
Non-cash changes, Debt forgiven/ Settlement/ Disposal	0	0
Non-cash changes, Accretion	0	0
Non-cash changes, Foreign exchange movements and change in estimates	215	224
Ending balance	$ 13,501	$ 9,815

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Convertible Debentures - YA II PN, Ltd. - USD ($) $ in Thousands	Aug. 27, 2024	Aug. 19, 2024	Aug. 16, 2024	Jul. 16, 2024
Disclosure of non-adjusting events after reporting period [line items]
Aggregate Principal Amount of Convertible Debentures Agreed to Sell and Issue				$ 3,000
Percentage of purchase price to aggregate principal amount				95%
Conversion of convertible debentures	$ 150	$ 150
Outstanding principal balance of of convertible debenture decrease amount	$ 300
Tranche Two
Disclosure of non-adjusting events after reporting period [line items]
Aggregate Principal Amount of Convertible Debentures Agreed to Sell and Issue			$ 1,000